US 12,311,010 B2
Formulated and/or co-formulated liposome compositions containing toll-like receptor(“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
David Stover, Los Angeles, CA (US); Dhruba Bharali, Sherman Oaks, CA (US); Bruce A Hay, Niskayuna, NY (US); and Tahmineh Safaie, Yucca Valley, CA (US)
Assigned to Nammi Therapeutics, Inc., Los Angeles, CA (US)
Filed by Nammi Therapeutics, Inc., Los Angeles, CA (US)
Filed on May 4, 2023, as Appl. No. 18/445,165.
Application 18/445,165 is a continuation of application No. 18/445,035, filed on Mar. 10, 2023.
Application 18/445,165 is a continuation of application No. 17/803,703, filed on Oct. 14, 2022, granted, now 11,896,646.
Application 18/445,165 is a continuation of application No. 17/300,227, filed on Apr. 16, 2021, granted, now 11,679,141.
Application 18/445,165 is a continuation of application No. 16/974,306, filed on Dec. 21, 2020, granted, now 11,744,874.
Prior Publication US 2023/0372442 A1, Nov. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 35/00 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); A61K 47/54 (2017.01); A61K 47/69 (2017.01)
CPC A61K 38/177 (2013.01) [A61K 45/06 (2013.01); A61K 47/543 (2017.08); A61K 47/6911 (2017.08)] 14 Claims
 
1. A method of treating a subject diagnosed with cancer comprising administering to a subject in need of such treatment an effective amount of a nanocarrier, wherein the nanocarrier comprises a Toll-like receptor (TLR) prodrug having the following structure

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.